INIFY LABORATORIES AB (WY60) - Total Assets
Based on the latest financial reports, INIFY LABORATORIES AB (WY60) holds total assets worth €204.64 Million EUR (≈ $239.25 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
INIFY LABORATORIES AB - Total Assets Trend (2021–2025)
This chart illustrates how INIFY LABORATORIES AB's total assets have evolved over time, based on quarterly financial data. Also see WY60 company net worth for the company's overall valuation and market capitalisation.
INIFY LABORATORIES AB - Asset Composition Analysis
Current Asset Composition (December 2025)
INIFY LABORATORIES AB's total assets of €204.64 Million consist of 48.6% current assets and 51.4% non-current assets. Review INIFY LABORATORIES AB (WY60) total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 40.9% |
| Accounts Receivable | €2.63 Million | 1.9% |
| Inventory | €1.72 Million | 1.2% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €2.19 Million | 1.6% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how INIFY LABORATORIES AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See WY60 stock price and chart for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: INIFY LABORATORIES AB's current assets represent 48.6% of total assets in 2025, a decrease from 100.0% in 2021.
- Cash Position: Cash and equivalents constituted 40.9% of total assets in 2025, down from 90.0% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 1.9% of total assets.
INIFY LABORATORIES AB Competitors by Total Assets
Key competitors of INIFY LABORATORIES AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Green Cross Lab Cell Corporation
KQ:144510
|
Korea | ₩335.22 Billion |
|
Monash Ivf Group Ltd
AU:MVF
|
Australia | AU$510.21 Million |
|
Scope Fluidics SA
WAR:SCP
|
Poland | zł141.67 Million |
|
Eurofins-Cerep SA
PA:ALECR
|
France | €88.84 Million |
|
Check-Cap Ltd
F:7CC
|
Germany | €7.49 Million |
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$16.78 Billion |
|
Integral Diagnostics Ltd
AU:IDX
|
Australia | AU$1.43 Billion |
|
Australian Clinical Labs Ltd
AU:ACL
|
Australia | AU$562.50 Million |
INIFY LABORATORIES AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.40 | 14.69 | 5.25 |
| Quick Ratio | 1.32 | 14.59 | 5.12 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €8.12 Million | €147.61 Million | €33.26 Million |
INIFY LABORATORIES AB - Advanced Valuation Insights
This section examines the relationship between INIFY LABORATORIES AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.67 |
| Latest Market Cap to Assets Ratio | 0.22 |
| Asset Growth Rate (YoY) | 227.6% |
| Total Assets | €140.55 Million |
| Market Capitalization | $30.74 Million USD |
Valuation Analysis
Below Book Valuation: The market values INIFY LABORATORIES AB's assets below their book value (0.22x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: INIFY LABORATORIES AB's assets grew by 227.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for INIFY LABORATORIES AB (2021–2025)
The table below shows the annual total assets of INIFY LABORATORIES AB from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €140.55 Million ≈ $164.32 Million |
+227.61% |
| 2024-12-31 | €42.90 Million ≈ $50.16 Million |
-53.87% |
| 2023-12-31 | €93.00 Million ≈ $108.73 Million |
-38.87% |
| 2022-12-31 | €152.13 Million ≈ $177.85 Million |
+30383.52% |
| 2021-12-31 | €499.05K ≈ $583.44K |
-- |
About INIFY LABORATORIES AB
INIFY Laboratories AB provides cancer diagnostics services in Sweden. It offers prostate cancer diagnostics services. The company was incorporated in 2021 and is based in Stockholm, Sweden.